Pulmonary drugs are medications used for the treatment and management of various respiratory diseases including asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis. These drugs help in relaxing the muscles in the airways and fighting against inflammation to provide relief in breathing difficulties.

The global Pulmonary Drugs Market is estimated to be valued at US$ 3.41 Bn in 2023 and is expected to exhibit a CAGR of 8.1% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:
The rising prevalence rates of asthma globally has been a major driver augmenting the growth of the pulmonary drugs market. As per recent statistical data, over 235 million people suffer from asthma across the world. Growing air pollution levels and changes in lifestyle and environment have contributed significantly to the increasing asthma patient pool. Consequently, the demand for various drugs types like bronchodilators, anti-inflammatory drugs, monoclonal antibodies, and combination therapies has witnessed a parallel rise over the past few years. This growing relapse of asthma cases worldwide has propelled the market size of pulmonary drugs during the forecast period.

SWOT Analysis

Strength: Presence of large number of players increases competition leading to product innovation. Weakness: High costs associated with R&D of novel drugs and therapies. Opportunity: Rising cases of respiratory diseases globally presents growth opportunity. Threats: Stringent regulatory approvals and lengthy clinical trials pose challenges.

Key Takeaways

The Global Pulmonary Drugs Market Demand is estimated to be valued at US$ 3.41 Bn in 2023 and is expected to exhibit a CAGR of 8.1% over the forecast period 2023 to 2030.

The North America region currently dominates the market owing to developed healthcare infrastructure and high adoption of advanced treatment therapies. Key players in the region are further investing in R&D to develop novel drugs.

Key players

Key players operating in the Pulmonary Drugs market are Sanofi SA, Meda Pharmaceuticals, Circassia Pharmaceuticals Plc., AstraZenca Plc., GlaxoSmithKline Plc., Mallinckrodt Pharmaceuticals Plc., Cheisi farmaceutici S.p.A., Zambon Company S.p.A., Alaxia SAS, and Merck Sharp & Dohme Limited. The market is expected to witness increased competition among these players resulting in portfolio expansion and strategic collaborations.

Get more insights on this topic: http://marketerefforts.weebly.com/home/pulmonary-drugs-market-is-estimated-to-driven-by-increasing-prevalence-of-respiratory-diseases